AMGEN INC (AMGN) - Price, trends, fundamentals and chart - Passport to Wall Street

AMGEN INC (NASDAQ: AMGN)

Overview

current price

$277.29

$277.29

change

-5.35 | -1.89%

-5.35 | -1.89%

Yesterday's Close

282.64

open

277.04

volume

4.37 M

30d. avg volume.

3.35 M

1 day

268.50 - 278.68

52 weeks

253.30 - 346.85

p/e

36.68

beta

0.5857

market cap

149.09 B

dividend yield

3.43%

Industry

-

News and Commentary

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on...

Market Update: Dow Climbs 100 Points as Year-End Strength Continues Stocks climbed higher Tuesday, even as investors grew concerned over the threat of new tariffs from President-elect Donald Trump. The Dow Jones Industrial Average rose over 100 p...

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In...

Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Willia... Technology giant NVIDIA Corp (

AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains AbbVie Inc (ABBV ...

Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administrati...

From Years to Months: How AI is Shaping the Landscape of Clinical Trials Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significan...

FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal The Federal Trade Commission (FTC) decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc

Rising Stars, Falling Trends: July's Industry ETF Winners and Losers As July comes to an end, it's time to take a look at the best- and worst-performing industry ETFs for the month.Among the largest ETFs that represent ma...

Drug Maker Games the Patent System to Rake in $114 Billion The pharmaceutical giant AbbVie (

StockTwits

StockTwits